BofA analyst Michael Ryskin upgraded 10x Genomics to Neutral from Underperform with a price target of $54, up from $36. The analyst says fading headwinds and an “impressive” launch from the Xenium platform are reasons to turn more constructive on the shares heading into 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TXG:
- 10x Genomics collaborates with NIH CARD on neuroscience research
- Curio Bioscience to ‘vigorously defend’ against 10x Genomics’ allegations
- NanoString downgraded to Neutral from Overweight at JPMorgan
- NanoString downgraded to Neutral from Outperform at Baird
- NanoString downgraded to Market Perform at TD Cowen after 10x Genomics ruling